US 12,240,879 B2
Interleukin-22 fusion proteins, and their pharmaceutical compositions
Ziyang Zhong, Belmont, CA (US); Fan Ye, Mountain View, CA (US); Jianing Huang, San Mateo, CA (US); Matthew Siegel, Menlo Park, CA (US); and Ji Wang, Castro Valley, CA (US)
Assigned to Anwita Biosciences, Inc., San Carlos, CA (US)
Filed by Anwita Biosciences, Inc., San Carlos, CA (US)
Filed on Jul. 29, 2021, as Appl. No. 17/388,129.
Claims priority of provisional application 63/059,137, filed on Jul. 30, 2020.
Prior Publication US 2022/0033454 A1, Feb. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/20 (2006.01); C07K 14/54 (2006.01); C07K 14/605 (2006.01); C07K 14/65 (2006.01); C07K 16/18 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/54 (2013.01) [C07K 14/605 (2013.01); C07K 14/65 (2013.01); C07K 16/18 (2013.01); A61K 38/00 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2319/30 (2013.01)] 25 Claims
 
1. A fusion protein comprising the amino acid sequence of Formula (I):

OG Complex Work Unit Chemistry
wherein:
D1 is an interleukin-22 domain and D2 is an albumin binding domain; or D1 is an albumin binding domain and D2 is an interleukin-22 domain; wherein the albumin binding domain is a VHH single domain antibody comprising: (i) the CDR1 of SEQ ID NO: 10, the CDR2 of SEQ ID NO: 11, and the CDR3 of SEQ ID NO: 12; or (ii) the CDR1 of SEQ ID NO: 18, the CDR2 of SEQ ID NO: 19, and the CDR3 of SEQ ID NO: 20;
DC and DN are each independently an interleukin-22 domain;
L1, LC, and LN are each independently a bond or a peptide linker; and
m and n are each independently an integer of 0 or 1;
wherein DC and DN are at the C-terminus and N-terminus of the fusion protein, respectively.